Story excerpt provided by Crain’s Cleveland Business.
Written by Rachel Abbey McCafferty and Chuck Soder.
Milo Biotechnology has received a patent on an experimental gene therapy designed to reverse muscular dystrophy.
The Cleveland company received a parent patent for “Myostatin Inhibition for Enhancing Muscle and/or Improving Muscle Function.”
Click here to read the complete article.
Originally published December 4, 2014.